VIVORYON THERAPEUTICS N.V.

Insiders Vivoryon Therapeutics N.V.

Equities

VVY

NL00150002Q7

Market Closed - Euronext Amsterdam Other stock markets 09:05:10 10/05/2024 pm IST			5-day change	1st Jan Change
0.795 ^EUR	-1.85%		+4.47%	-90.23%

24/04	Transcript : Vivoryon Therapeutics N.V., 2023 Earnings Call, Apr 24, 2024
15/03	Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	CI

Insiders

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Vivoryon Therapeutics N.V Announces Resignation of Board of Directors	15/03	CI
Vivoryon Therapeutics N.V. Announces Board Appointments	15/23/15	CI
Vivoryon Therapeutics Promotes Chief Medical Officer to CEO	07/23/07	MT
Vivoryon Therapeutics N.V. Approves Board Appointments	21/23/21	CI
Vivoryon Therapeutics CEO to Step Down in FY24	16/23/16	MT
Vivoryon Therapeutics N.V. Announces Resignation of Ulrich Dauer as CEO	15/23/15	CI
Vivoryon Therapeutics N.V. Announces Resignation of Dinnies Johannes Von Der Osten, PhD, and Jörg Neermann, PhD from the Board of Directors	01/23/01	CI
Vivoryon Therapeutics N.V. Announces the Appointment of Dr. Claudia Riedl and Samir Shah to its Non-Executive Board of Directors	22/22/22	CI
Probiodrug AG has Changed its Name to Vivoryon Therapeutics AG	11/19/11	CI
Probiodrug AG Announces Management Changes	05/18/05	CI
Probiodrug AG Appoints Michael Schaeffer as Executive Vice President of Business and Strategy	04/18/04	CI
Probiodrug AG Announces Management Changes	23/18/23	CI
Probiodrug AG Announces Management Changes	12/16/12	CI
Probiodrug AG Appoints Mark Booth as Chief Business Officer	23/16/23	CI
Probiodrug AG Appoints Inge Lues as Member of the Management Board as Chief Development Officer	31/14/31	CI
Probiodrug AG Appoints Ronald Black as Chief Medical Officer and Inge Lues as Chief Development Officer	23/13/23	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

SIGN UP NOW